David B. Musket - Jun 29, 2022 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Role
Director
Signature
/s/ Linda Marban, Attorney-in-Fact
Stock symbol
CAPR
Transactions as of
Jun 29, 2022
Transactions value $
-$91,364
Form type
4
Date filed
7/1/2022, 09:00 PM
Previous filing
Jun 29, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAPR Common Stock Sale -$106K -28.2K -68.88% $3.77 12.7K Jun 29, 2022 Direct F1
transaction CAPR Common Stock Options Exercise $15K +10.8K +84.69% $1.39 23.5K Jun 30, 2022 Direct
holding CAPR Common Stock 7.1K Jun 29, 2022 Held by Reporting Person's IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -1.4K -100% $0.00* 0 Jun 30, 2022 Common Stock 1.4K $1.39 Direct F2, F3
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -4.75K -100% $0.00* 0 Jun 30, 2022 Common Stock 4.75K $1.39 Direct F4
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -4.65K -100% $0.00* 0 Jun 30, 2022 Common Stock 4.65K $1.39 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.76 to $3.80, inclusive. The reporting person undertakes to provide to Capricor Therapeutics, Inc., any security holder of Capricor Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F3 25% of the shares of common stock vested immediately, with the remainder vesting 1/36th of the first day of each month, commencing May 1, 2013.
F4 This option was granted on March 3, 2015 and was previously reported as covering 47,500 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F5 This option was granted on June 2, 2016 and was previously reported as covering 46,458 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F6 2,250 shares vested immediately on June 2, 2016. The remaining shares vested on December 31, 2016.